Thursday, November 19, 2026 Latest Ford Begins LFP Cell Production, Fueling Fathom Pickup Prototypes Our standards
News

White House Withdraws Heidi Overton FDA Nomination, Sources Say

The White House has withdrawn the nomination of Dr. Heidi Overton to lead the Food and Drug Administration, a White House official confirmed on Tuesday.

White House Withdraws Heidi Overton FDA Nomination, Sources Say
White House Withdraws Heidi Overton FDA Nomination, Sources Say

The White House has withdrawn the nomination of Dr. Heidi Overton to lead the Food and Drug Administration, a White House official confirmed on Tuesday.

The decision came just a day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on whether to advance her nomination to the full Senate, according to NBC News.

President Donald Trump nominated Overton in August following the resignation of former FDA Commissioner Marty Makary in May, turning to a preventive medicine physician and deputy director of the White House Domestic Policy Council to steady an agency that has lost more than 4,500 staff over the past year, according to CNBC.

Confirmation Hurdles and Senate Opposition

Overton faced a narrow path to confirmation in the Senate committee, where Republicans held a one-seat advantage over Democrats, meaning she could not afford a single Republican defection to advance, according to The Guardian.

Committee Chairman Bill Cassidy, R-La., had previously called her support for Trump’s plan to break up combination vaccines “almost disqualifying” and pressed her during a September hearing about her scientific independence from Trump and Health Secretary Robert F. Kennedy Jr., according to The Guardian.

At the same time, other Republican senators raised concerns over policy positions and regulatory decisions. Senator Susan Collins, R-Maine, told NBC News she was undecided and needed answers on various issues, while Senator Lisa Murkowski, R-Alaska, questioned Overton during her hearing about political pressure surrounding access to the abortion pill mifepristone and criticized her for not taking a clear position.

Outside advocacy groups also targeted the nominee, with a nonpartisan advocacy group called Health in Office launching a campaign in Washington and other cities branding her “Heidi Vaperton” over the FDA’s May authorization of fruit-flavored vapes, according to CNBC.

Disagreements Over Abortion Policy

While policy disputes centered heavily on vaccines and vaping, Cassidy suggested that the withdrawal ultimately stemmed from an impasse over abortion commitments rather than health standards.

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton. My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk. The last issue was that pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues. The Administration withdrew Dr. Overton rather than make such commitments. Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats,” Cassidy said.

said Bill Cassidy according to NBC News.

White House Withdraws Heidi Overton FDA Nomination, Sources Say
Photo: cnbc.com

Overton has praised the Supreme Court’s decision to overturn Roe v. Wade and previously called for strict restrictions on medication abortion in a 2023 policy brief for the conservative America First Policy Institute, where she wrote that abortion is corrosive to society and criticized federal mailing policies for abortion pills, according to The Guardian.

The FDA is currently conducting a safety review of mifepristone at Trump’s request, with a report promised by March, according to Reflector.

Meanwhile, reproductive rights organizations celebrated the withdrawal, with Reproductive Freedom for All President and CEO Mini Timmaraju stating that Overton posed a serious threat to medication abortion access, according to The Guardian.

With Republicans racing to confirm nominees before handing Senate control over to Democrats in January, it remains unclear whether the White House will put forward another permanent nominee or if the vacancy will persist under acting commissioner Kyle Diamantas, according to Reflector and CNBC.

Accuracy matters. See something that needs attention? Read our corrections policy or contact the newsroom.

World Editor

Samira Rahman

Samira Rahman leads TellingPointy's World desk. Her coverage follows diplomacy, conflict, migration, security, climate, and global institutions through the decisions that shape public life, distinguishing verified developments from unconfirmed claims.